Document information 28/01/2012 12:52
Current documents
SPC 4875
PIL 3866
Total: 8741
Submissions in the last 3 months
Updated: 1344
New: 533
Yellow card logo - report a suspected side effect
Drug Saftey Update logo
Search using the dm+d Browser

title icon
What's New

These are the latest new, updated and retired (removed) Summaries of Product Characteristics (known as SPCs or SmPCs) and Patient Information Leaflets (known as PILs, Package Leaflets or PLs) on the eMC website. More help.

Filter Results

Document Type:
PIL SPC
Status:  
New Update Retired
27 January 2012
New 4, Updated 31, Retired 0, [Total 35]
Active Ingredients / Generics: propafenone hydrochloride
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
Active Ingredients / Generics: budesonide
  • Change to section 4.4 - Special warnings and precautions for Use
Active Ingredients / Generics: bumetanide
  • Change to section 6. 3 - Shelf Life
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: bumetanide
  • Change to section 6. 3 - Shelf Life
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: citalopram hydrochloride
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to side-effects
  • Change to drug interactions
  • Change to dosage and administration
Active Ingredients / Generics: citalopram hydrochloride
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: citalopram hydrobromide
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: citalopram hydrobromide
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to side-effects
  • Change to drug interactions
  • Change to dosage and administration
Active Ingredients / Generics: pancreatin
  • Change to side-effects
Active Ingredients / Generics: pancreatin
  • Change to side-effects
Active Ingredients / Generics: pancreatin
  • Change to side-effects
Active Ingredients / Generics: pancreatin
  • Change to side-effects
Active Ingredients / Generics: hepatitis b vaccine (rDNA)
  • Change to date of revision
  • Change to warnings or special precautions for use
Active Ingredients / Generics: econazole nitrate
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.9 - Overdose
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: econazole nitrate
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.9 - Overdose
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: econazole nitrate
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.9 - Overdose
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: latanoprost
  • New PIL for new product
Active Ingredients / Generics: timolol maleate, latanoprost
  • New PIL for new product
Active Ingredients / Generics: methylprednisolone sodium succinate
  • New PIL for new product
Active Ingredients / Generics: methylprednisolone sodium succinate
  • New PIL for new product
Active Ingredients / Generics: sertraline hydrochloride
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change of contra-indications
  • Change to side-effects
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: sunitinib malate
  • Correction of spelling/typing errors
Active Ingredients / Generics: tick borne encephalitis virus
  • Change to section 6. 3 - Shelf Life
Active Ingredients / Generics: lidocaine
  • Change to how the medicine works
  • Change to date of revision
Active Ingredients / Generics: lidocaine hydrochloride, adrenaline tartrate
  • Improved Electronic Presentation
Active Ingredients / Generics: levocetirizine dihydrochloride
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.2 - Pharmacokinetic Properties
Active Ingredients / Generics: ondansetron hydrochloride dihydrate
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: ondansetron
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: ondansetron
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: ondansetron
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: ondansetron hydrochloride dihydrate
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: ondansetron hydrochloride dihydrate
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: ondansetron hydrochloride dihydrate
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
26 January 2012
New 5, Updated 28, Retired 11, [Total 44]
Active Ingredients / Generics: spironolactone, hydroflumethiazide
  • Change to Marketing Authorisation Holder
PIL retired Amaryl
Active Ingredients / Generics: glimepiride
Company: sanofi-aventis
  • PIL Product / presentation discontinued
SPC retired Amaryl
Active Ingredients / Generics: glimepiride
Company: sanofi-aventis
  • SPC Product / presentation discontinued
PIL retired Apidra 100 U/ml solution for injection in OptiClik cartridge
Active Ingredients / Generics: insulin glulisine
Company: sanofi-aventis
  • PIL Product / presentation discontinued
SPC retired Apidra 100 Units/ml solution for injection in a cartridge for OptiClik
Active Ingredients / Generics: insulin glulisine
Company: sanofi-aventis
  • SPC Product / presentation discontinued
Active Ingredients / Generics: oxymetazoline hydrochloride
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: colistin sulphate
  • Change to section 4.2 - Posology and method of administration
Active Ingredients / Generics: metformin hydrochloride, pioglitazone hydrochloride
  • Correction of spelling/typing errors
PIL retired Cordarone X 100, Cordarone X 200
Active Ingredients / Generics: amiodarone hydrochloride
Company: sanofi-aventis
  • PIL Product / presentation discontinued
SPC retired Cordarone X 100, Cordarone X 200
Active Ingredients / Generics: amiodarone hydrochloride
Company: sanofi-aventis
  • SPC Product / presentation discontinued
Active Ingredients / Generics: liquid paraffin, benzalkonium chloride, isopropyl myristate, chlorhexidine dihydrochloride
  • Change to Further Information section
  • Change to date of revision
Active Ingredients / Generics: liquid paraffin, benzalkonium chloride, isopropyl myristate, chlorhexidine dihydrochloride
  • Change to Further Information section
  • Change to date of revision
PIL retired Dicynene
Active Ingredients / Generics: etamsylate
Company: sanofi-aventis
  • Licence Withdrawn
SPC retired Dicynene 500 Tablets
Active Ingredients / Generics: etamsylate
Company: sanofi-aventis
  • Licence Withdrawn
Active Ingredients / Generics: fluconazole
Company: Pfizer Limited
  • New individual SPC (was previously included in combined SPC)
Active Ingredients / Generics: fluconazole
Company: Pfizer Limited
  • New individual SPC (was previously included in combined SPC)
Active Ingredients / Generics: fluconazole
Company: Pfizer Limited
  • New individual SPC (was previously included in combined SPC)
Active Ingredients / Generics: propofol
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: propofol
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: liquid paraffin
  • Change to Further Information section
  • Change to date of revision
Active Ingredients / Generics: liquid paraffin, isopropyl myristate
  • Change to Further Information section
  • Change to date of revision
PIL retired Eloxatin 5 mg/ml concentrate for solution for infusion
Active Ingredients / Generics: oxaliplatin
Company: sanofi-aventis
  • PIL Product / presentation discontinued
SPC retired Eloxatin 5 mg/ml concentrate for solution for infusion
Active Ingredients / Generics: oxaliplatin
Company: sanofi-aventis
  • SPC Product / presentation discontinued
Active Ingredients / Generics: acarbose
  • Change to date of revision
Active Ingredients / Generics: acarbose
  • Change to date of revision
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: poliomyelitis vaccine, diphtheria, tetanus and pertussis vaccine
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 10 date of revision of the text
PIL retired Insuman Basal Optiset
Active Ingredients / Generics: human insulin
Company: sanofi-aventis
  • PIL Product / presentation discontinued
Active Ingredients / Generics: midazolam hydrochloride
  • Addition of joint PIL covering all presentations
Active Ingredients / Generics: midazolam hydrochloride
  • Addition of joint PIL covering all presentations
Active Ingredients / Generics: midazolam hydrochloride
  • Individual presentations superseded by joint PIL
Active Ingredients / Generics: pegfilgrastim
  • Change due to user-testing of patient information
Active Ingredients / Generics: ritonavir
  • Change to date of revision
  • Change to side-effects
Active Ingredients / Generics: ritonavir
  • Change to date of revision
  • Change to side-effects
Active Ingredients / Generics: xylometazoline hydrochloride
  • New SPC for new product
Active Ingredients / Generics: guaifenesin, pseudoephedrine hydrochloride
  • Change to section 4.9 - Overdose
Active Ingredients / Generics: sodium fusidate
  • Change to Further Information section
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to side-effects
  • Change to drug interactions
  • Change to name of manufacturer
Active Ingredients / Generics: nilotinib hydrochloride monohydrate
  • Change to Further Information section
Active Ingredients / Generics: nilotinib hydrochloride monohydrate
  • Change to Further Information section
Active Ingredients / Generics: tramadol hydrochloride
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: typhoid vaccine
  • Change to date of revision
  • Change to warnings or special precautions for use
Active Ingredients / Generics: diclofenac sodium
  • New SPC for new product
Active Ingredients / Generics: tramadol hydrochloride
  • Change to section 6. 4 - Special Precautions for Storage
25 January 2012
New 0, Updated 39, Retired 4, [Total 43]
Active Ingredients / Generics: acwy meningococcal polysaccharide
  • Change to date of revision
  • Change to warnings or special precautions for use
Active Ingredients / Generics: acwy meningococcal polysaccharide
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: amikacin sulfate
  • Change/addition of instructions for reconstitution and/ or administration
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to information about pregnancy or lactation
Active Ingredients / Generics: ofatumumab
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: levobupivacaine hydrochloride
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 10 date of revision of the text
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 10 date of revision of the text
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: beclometasone dipropionate
  • Change to Further Information section
  • Change to date of revision
Active Ingredients / Generics: colistin sulphate
  • Addition of separate PILs covering individual presentations
  • Change to dosage and administration
Active Ingredients / Generics: medroxyprogesterone acetate
  • Change to date of revision
  • Change to Marketing Authorisation Holder
Active Ingredients / Generics: medroxyprogesterone acetate
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: fluconazole
  • Improved Electronic Presentation
Active Ingredients / Generics: fluconazole
  • Correction of spelling/typing errors
Active Ingredients / Generics: fluconazole
  • Correction of spelling/typing errors
Active Ingredients / Generics: fluconazole
  • Correction of spelling/typing errors
Active Ingredients / Generics: fluconazole
  • Correction of spelling/typing errors
Active Ingredients / Generics: propofol
  • Change to date of revision
  • Change to side-effects
Active Ingredients / Generics: propofol
  • Change to date of revision
  • Change to side-effects
PIL retired Doxorubicin Hydrochloride 2 mg/ml solution for infusion (hameln)
Active Ingredients / Generics: doxorubicin hydrochloride
  • PIL Product / presentation discontinued
  • Change to section 4.2 - Posology and method of administration
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: hepatitis b vaccine (rDNA)
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: hepatitis b vaccine (rDNA)
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 10 date of revision of the text
  • Change to date of revision
  • Change to warnings or special precautions for use
PIL retired Epirubicin hydrochloride 2mg/ml solution for injection or infusion (hameln)
Active Ingredients / Generics: epirubicin hydrochloride
  • PIL Product / presentation discontinued
Active Ingredients / Generics: acarbose
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: acarbose
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: hydrocortisone acetate
  • Change of licence holder
Active Ingredients / Generics: hepatitis a vaccine, typhoid vaccine
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: hepatitis a vaccine, typhoid vaccine
  • Change to date of revision
  • Change to warnings or special precautions for use
Active Ingredients / Generics: poliomyelitis vaccine, diphtheria, tetanus and pertussis vaccine
  • Change to date of revision
  • Change to warnings or special precautions for use
Active Ingredients / Generics: rufinamide
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
PIL retired Modrenal
Active Ingredients / Generics: trilostane
  • Licence Withdrawn
SPC retired Modrenal
Active Ingredients / Generics: trilostane
  • Licence Withdrawn
Active Ingredients / Generics: ondansetron hydrochloride dihydrate
  • Change to dosage and administration
Active Ingredients / Generics: tamsulosin hydrochloride
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 6.1 - List of Excipients
Active Ingredients / Generics: pantoprazole sodium sesquihydrate
  • Change to section 4.8 - Undesirable Effects
Active Ingredients / Generics: nilotinib hydrochloride monohydrate
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
Active Ingredients / Generics: nilotinib hydrochloride monohydrate
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
Active Ingredients / Generics: tramadol hydrochloride
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
Active Ingredients / Generics: trimethoprim
  • Change to side-effects
Active Ingredients / Generics: typhoid vaccine
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: denosumab
  • Change to section 6. 5 - Nature and Contents of Container
Active Ingredients / Generics: tramadol hydrochloride
  • Change to storage instructions